#Incretin mimetics
GLP-1, GIP, glucagon receptor agonists.
GLP-1 Drugs and Psoriasis Healthcare Use
A new JEADV letter examines whether GLP-1 and GLP-1/GIP drugs like tirzepatide and semaglutide change healthcare use in psoriasis patients.
The trade-offs of widespread GLP-1 use
GLP-1 medicines have strong trial evidence, but widespread use also raises questions about access, marketing, and evidence beyond the headlines.
GLP-1 injection site reactions explained
Tirzepatide, semaglutide and other GLP-1 drugs cause injection site and skin reactions in about a third of reported adverse events, an FDA data review finds.
GLP-1 Receptor Agonists and Sleep Apnea
Tirzepatide holds a US FDA approval for sleep apnea backed by SURMOUNT-OSA data. Here is what the evidence supports for the GLP-1 receptor agonist class.
US employers pulling GLP-1 coverage in 2027
About 14% of large US employers have dropped or plan to drop GLP-1 obesity drug coverage in 2027, as pharmacy costs hit 25% of total healthcare spend.
GLP-1 Drugs and Kidney Fibrosis in Mice
A new mouse study compared semaglutide, tirzepatide and retatrutide on kidney fibrosis. Here is what the animal data does and does not show.
Switching to Tirzepatide: Liver Fibrosis
A Japanese study found switching from other GLP-1 drugs to tirzepatide reduced FIB-4 liver fibrosis scores in high-risk patients.
Can incretins ease psoriasis inflammation?
A 2026 editorial asks whether tirzepatide-class incretin therapy quiets inflammation biologics leave behind in psoriasis. A hypothesis, not a trial result.
What is GEP44? A GLP-1/PYY explainer
GEP44 is an investigational peptide that pairs GLP-1 with peptide YY signalling to test whether weight loss can come with fewer GI side effects.
COMBINE 4: IcoSema vs insulin glargine
COMBINE 4 put once-weekly IcoSema against daily insulin glargine U100 in type 2 diabetes. HbA1c fell further, and bodyweight moved the other way.
Do GLP-1 drugs cause throat symptoms?
A 2026 Laryngoscope cohort ties GLP-1 drugs to cough, globus and voice change. Here is what an association study can and cannot show.
Stapled semaglutide variants, explained
A new chemistry paper built stapled variants of a semaglutide fragment that last longer in serum; here is what that does and does not show.